Joy Maulik, CRNP, on the growing role of PARP inhibitors in prostate cancer

Author(s):

Key Takeaways

PARP inhibitors are gaining importance in prostate cancer treatment, offering alternatives to androgen deprivation therapy.
Treatment strategies from breast and pancreatic cancer are being adapted for prostate cancer, potentially improving patient survival.
Recent studies indicate that PARP inhibitors like olaparib can benefit high-risk prostate cancer patients.
Embracing new data and treatment options can provide hope and improved outcomes for patients and caregivers.

“When a patient knows that there are so many tools that are there for people, it gives them hope. It gives their caregivers hope,” says Joy Maulik, CRNP.

In this video, Joy Maulik, CRNP, shares the key take-home message from the session, “Advanced Prostate Cancer Clinics – Genetic testing/PARP,” which was presented at the 2024 LUGPA Annual Meeting in Chicago, Illinois. Maulik is a urology nurse practitioner at Chesapeake Urology in Salisbury, Maryland.

Video Transcript:

Could you recap your LUGPA session?

We had a very engaging conversation during the talk, and that was good to see how many people are interested in understanding how we can use PARPs. The biggest takeaway from that was that we got more people aware that there is different layering of treatment for prostate cancer and does not have to be only androgen deprivation-related. Nuances and exploring other options that have been used for breast cancer and pancreatic cancer and other sorts, we can now bring that right to prostate cancer and give patients a longer survival rate.

Could you expand on the growing importance and the growing role of PARP inhibitors in prostate cancer?

Huge. We discussed a little bit about that JAMA Oncology paper. They're doing studies now, even for high-risk BCR patients would not even giving them androgen deprivation therapy and just using PARPs, olaparib, and people are surviving longer. If we can understand that at the end of the day, it's not what we are comfortable with, but we get comfortable with the data. We broaden our horizons to learn new things and bring things up, end of the day, patients are going to be the beneficiary of that. I think they deserve that, because cancer, like I said in the last time, is a very emotional diagnosis. When a patient knows that there are so many tools that are there for people, it gives them hope. It gives their caregivers hope.

This transcript was AI generated and edited by human editors for clarity.